Work

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

FWCI: 6.738
Cites: 26
Cited by: 232
Related to: 10